Robert S. Svatek, MD, outlines unmet needs in NMIBC

In an interview at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, Robert S. Svatek, MD, MSCI, highlighted some of the greatest unmet needs in the non–muscle invasive bladder cancer (NMIBC) space. Svatek is a professor and the Gary and Glenda Woods President’s Distinguished University Chair in GU Oncology at UT Health San Antonio in Texas.

To begin the discussion, Svatek notes the lack of effective screening tools as one of the earliest and most important unmet needs in the bladder cancer landscape. While prior work from investigators such as Edward M. Messing, MD, and Yair Lotan, MD, suggests that screening strategies may help prevent tumor development, a standardized and clinically practical approach has yet to be established. He notes that this remains an emerging area of research with potential to shift how clinicians approach early detection and prevention in at-risk populations.

For patients who have already developed NMIBC, Svatek emphasizes that recurrence represents the more pervasive clinical challenge. Frequent tumor recurrence places a substantial burden on patients, who must undergo repeated cystoscopic surveillance and intravesical treatments administered via catheter. Although many currently available therapies demonstrate activity, their long-term durability remains suboptimal, underscoring the need for treatment strategies that can maintain disease control over extended periods. He points to oral therapies as a promising future direction that may offer both improved tolerability and a more convenient route of administration.

Finally, Svatek discusses the importance of better identifying the subset of patients who do progress to more advanced disease. Advances in understanding tumor biology, including recognition of high-risk histologic variants such as micropapillary disease, have improved clinicians’ ability to stratify risk. Continued refinement in molecular and phenotypic characterization may ultimately enable more personalized treatment selection, allowing clinicians to intervene earlier and tailor management strategies based on the underlying biology of each patient’s disease.